Data / Drug companies / Fexofenadine hydrochloride, pseudoephedrine hydrochloride
Fexofenadine hydrochloride, pseudoephedrine hydrochloride: 4 companies and 4 products in the FDA NDC directory
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Fexofenadine hydrochloride, pseudoephedrine hydrochloride is listed in the FDA National Drug Code Directory by 4 companies, with 4 products in commercial distribution. 4 of the products (100.0%) are marketed under an abbreviated new drug application (ANDA), the generic route. The most common dosage forms are tablet, film coated, extended release, and the newest product started marketing on August 6, 2026.
The request: Get every company that lists fexofenadine hydrochloride, pseudoephedrine hydrochloride in the FDA NDC directory, with headquarters, website and number of employees. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Companies listing it
- 4
- Products
- 4
- Generic (ANDA) products
- 4 (100.0%)
- Application numbers
- 1
- Routes
- Oral
- Brand names
- Leader 12HR Allergy and Congestion Relief, Foster and Thrive Allergy and Congestion D, Rugby Allergy Relief D, Equate Allergy Relief D
- openFDA record search
- api.fda.gov
Companies that list fexofenadine hydrochloride, pseudoephedrine hydrochloride
Ranked by number of products. Finished drugs in commercial distribution.
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| Cardinal Health 110, LLC. DBA Leader | 1 | tablet, film coated, extended release | Generic drugs (ANDA) | August 3, 2026 |
| Rugby Laboratories | 1 | tablet, film coated, extended release | Generic drugs (ANDA) | July 8, 2026 |
| Strategic Sourcing Services LLC | 1 | tablet, film coated, extended release | Generic drugs (ANDA) | February 11, 2026 |
| Walmart Inc. | 1 | tablet, film coated, extended release | Generic drugs (ANDA) | August 6, 2026 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet, film coated, extended release | 4 | 100% |
Marketing categories
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 4 | 100% |
Pharmacologic classes
| Class | Products |
|---|---|
| Histamine-1 Receptor Antagonist | 4 |
| alpha-Adrenergic Agonist | 4 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.